Subjects diagnosed with COPD and meet the following standards: a.sustained airway obstruction; b.presence of persistent airflow limitation confirmed by post-bronchodilator FEV1\<70% predicted value and FEV1/FVC \< 0.7.
Subjects with pulmonary emphysema confirmed by imaging evidence.
Subjects with DLCO\<80% predicted value in pulmonary function test.
Subjects with stable condition for more than 4 weeks.
Subjects tolerant to bronchoscopy.
Subjects signed informed consent.
You may not be if
Pregnant or lactating women.
Subjects with syphilis or any of HIV, HBV, HCV positive antibody.
Subjects with any malignancy.
Subjects suffering from any of the following pulmonary diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary artery hypertension or interstitial lung disease.
Subjects suffering from other serious diseases, such as diabetes, myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis.
Subjects with leukopenia (WBC less than 4x10\^9 / L) or agranulocytosis (WBC less than 1.5x10\^9 / L or neutrophils less than 0.5x10\^9 / L) caused by any reason.
Subjects with severe renal impairment, serum creatinine\> 1.5 times of the upper limit of normal.
Subjects with liver disease or liver damage: ALT, AST, total bilirubin\> 2 times of the upper limit of normal.
Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
Subjects with a history of alcohol or illicit drug abuse.
Subjects accepted by any other clinical trials within 3 months before the enrollment.
Subjects with poor compliance, difficult to complete the study.
Any other conditions that might increase the risk of subjects or interfere with the clinical trial.
Clareo Health | Autologous Transplantation of Bronchial Basal Cells for Treatment of COPD
